Replies to post #767202 on NorthWest Biotherapeutics Inc (NWBO)

[vator]

Good grief is right. You seem to forget in your recent posts ALL cancer. So the Danish probably with the help of AI fabricated the NHS chart. Plausible but probably not.

[beartrap12]

Dennis, I looked up the relationship between MHRA, NICE, and NHS because I realized I didn't understand it, so maybe others can benefit from this, which I got from google IA:

MHRA (Medicines and Healthcare products Regulatory Agency):
MHRA is responsible for ensuring that medicines, medical devices, and blood components for transfusion are safe, effective, and meet required standards in the UK. They conduct rigorous assessments and provide licensing for these products.
NHS (National Health Service):
The NHS is the UK's state-funded healthcare system. It provides a wide range of healthcare services, and the availability of new and existing treatments within the NHS is heavily influenced by NICE guidance.
NICE (National Institute for Health and Care Excellence):
NICE provides guidance and recommendations on the use of healthcare technologies and treatments, including medicines and medical devices. They assess the clinical effectiveness and cost-effectiveness of these technologies to determine whether they should be funded by the NHS.
Relationship:
The MHRA's approval is a prerequisite for a medicine or device to be considered by NICE for potential NHS funding.
NICE's technology appraisals, which assess the clinical and cost-effectiveness, are crucial for determining which treatments will be available on the NHS.
MHRA and NICE work collaboratively to ensure timely guidance from NICE, with NICE aiming to publish final guidance within 90 days of receiving marketing authorization from MHRA.
The government is also working on enhancing collaboration between MHRA and NICE, including a pilot for concurrent MHRA marketing authorization and NICE technology appraisal.